secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001439222-24-000032
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q4 net loss $95.9M; positive mitapivat Phase 3 for NTD thalassemia
------------------------------------------------------------------------

- Q4 PYRUKYND US net revenue $7.1M (down 4% QoQ); full year 2023 $26.8M.
- Net loss $95.9M in Q4 vs net income $36.5M in Q4 2022; full year loss $352.1M.
- Positive Phase 3 ENERGIZE study in non-transfusion-dependent thalassemia met primary endpoint.
- Cash & equivalents $806.4M; company expects runway into 2026.
- Pipeline milestones: ENERGIZE-T data mid-2024; FDA filing for mitapivat in thalassemia end-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922224000032/0001439222-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922224000032/agio-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001439222-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer